Ivabradine - Servier

Drug Profile

Ivabradine - Servier

Alternative Names: AMG-998; Coralan; Coraxan; Corlanor; Corlentor; Ivabradine hydrochloride; LANCORA; ONO-1162; Procoralan; S-16257; S-16257-2; S-57

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Servier
  • Developer Amgen; Ono Pharmaceutical; Servier; University of California, San Diego
  • Class Benzazepines; Bradycardic agents; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Hyperpolarisation activated cation channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angina pectoris; Chronic heart failure
  • Phase III Coronary artery disease; Tachycardia
  • Phase II Low cardiac output

Most Recent Events

  • 31 Jul 2017 Servier terminates a phase-II trial in Healthy volunteers in United Kingdom (PO) (EudraCT2012-005627-32)
  • 20 Jun 2017 Phase-III clinical trials in Tachycardia (postural orthostatic tachycardia syndrome) in USA (PO) (NCT03182725)
  • 10 Jan 2017 Registered for Chronic heart failure in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top